Suyash Prasad - Feb 23, 2022 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
CMO and Head of R&D
Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Feb 23, 2022
Transactions value $
$0
Form type
4
Date filed
2/25/2022, 03:20 PM
Previous filing
Jul 1, 2021
Next filing
Apr 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +80.7K $0.00 80.7K Feb 23, 2022 Common Stock 80.7K $5.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.